Next Article in Journal
The Role of Robot-Assisted Radical Prostatectomy in the Management of Prostate Cancer and Future Perspectives
Previous Article in Journal
Radiomics-Driven Tumor Prognosis Prediction Across Imaging Modalities: Advances in Sampling, Feature Selection, and Multi-Omics Integration
Previous Article in Special Issue
RNA-Independent Regulatory Functions of lncRNA in Complex Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 19
10.3390/cancers17193123
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Investigating the Relationship Between Long Non-Coding RNAs and miR-200 Family Expression in Clear Cell Renal Cell Carcinoma

by
Tanja Čugura
,
Nina Hauptman
,
Jera Jeruc
and
Emanuela Boštjančič
*
Institute of Pathology, Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(19), 3123; https://doi.org/10.3390/cancers17193123
Submission received: 2 August 2025 / Revised: 19 September 2025 / Accepted: 21 September 2025 / Published: 25 September 2025
(This article belongs to the Special Issue State-of-the-Art Strategies for Non-Coding RNA Function Detection and Regulation in Cancer)
Browse Figures
Versions Notes

Simple Summary

Non-coding RNAs (ncRNAs) are a class of RNA molecules that do not encode proteins and primarily serve regulatory functions. They are categorized by length into small ncRNAs (e.g., microRNAs) and long non-coding RNAs (lncRNAs). The microRNAs of the miR-200 family are well-known inhibitors of epithelial-to-mesenchymal transition (EMT). In our previous studies, we observed miR-200 family downregulation in renal cell carcinoma (RCC). However, there is limited data regarding the regulation of miR-200 family expression by lncRNAs in RCC. Our results indicate that miR-200 family expression in RCC correlates at least in part with the expression of lncRNAs. This work emphasizes the significance of the complex network of different classes of ncRNAs that may contribute to the development of RCC and could be crucial for establishing new biomarkers and for developing new treatment modalities for advanced, incurable forms of RCC.

Abstract

Objectives: MicroRNAs of the miR-200 family are recognized as key inhibitors of epithelial-to-mesenchymal transition (EMT). However, there is limited data on the potential regulation of miR-200 family expression by long non-coding RNAs (lncRNAs) in RCC. Methods: We conducted a comprehensive literature and database search to identify lncRNAs that had been already functionally validated as regulators of any member of the miR-200 family. We analyzed the expression levels of the miR-200 family and the identified lncRNAs by qPCR. The study included 42 samples of carcinoma and non-carcinoma tissue from 25 RCC patients. In addition, we used RNA sequencing data from The Cancer Genome Atlas (TCGA), encompassing 511 kidney RCC (KIRC) samples, to further analyze the expression of miRNAs and lncRNAs. Results: We identified 127 lncRNAs with confirmed regulatory functions, 31 of which were validated in our samples. The majority of lncRNAs, along with all members of the miR-200 family, showed consistent downregulation in carcinoma tissues compared to non-carcinoma tissues. We observed a significant correlation between the expression of at least one member of the miR-200 family and 17 lncRNAs. In particular, three lncRNAs (MALAT1, OIP5-AS1, and LINC00467) showed a correlation with the expression of all members of the miR-200 family. Our results were at least partially confirmed in KIRC samples from the TCGA dataset. Conclusions: Our results suggest that the expression of the miR-200 family in RCC might be at least partially influenced by lncRNAs. Based on our cohort of samples, MALAT1, OIP5-AS1, and LINC00467 appear to be potentially important contributors to RCC development.

Graphical Abstract

1. Introduction

Non-coding RNAs (ncRNAs) are a class of RNA molecules that do not encode proteins. Less than 5% of the human genome is actively transcribed into messenger RNAs (mRNAs) and protein-coding genes, while the remainder consists of non-coding genes, known as ncRNAs [1]. Although primarily regulatory in function, many ncRNAs have been identified as potential tumor suppressors and/or oncogenes, exhibiting greater specificity for cell and tissue types compared to mRNAs [2,3,4,5]. ncRNA-mediated gene silencing plays a crucial role in regulating biological processes essential for cellular homeostasis. The discovery of ncRNAs significantly enhanced our understanding of various physiological and pathological processes. Functional analyses of many ncRNAs have revealed their key roles in cell cycle regulation, epigenetic regulation, genomic imprinting, cell differentiation, and apoptosis, as well as in various pathologic processes including carcinogenesis. They influence the invasiveness and progression of different carcinomas by regulating a variety of processes, including epithelial–mesenchymal transition (EMT) [6,7,8,9].
ncRNAs can be classified into two main categories: small RNAs, which are less than 200 nucleotides (nt), and long non-coding RNAs (lncRNAs), which are more than 200 nt and extend up to 100 kb [10]. Among small RNAs, microRNAs (miRNAs), typically ranging from 20 to 26 nt, are the most extensively studied, functioning mainly as post-transcriptional regulators of gene expression. Unlike mRNAs, miRNAs lack a 5′ cap and a poly-A tail [11]. They can be expressed as single genes, in gene clusters, or from introns of both protein-coding and non-protein-coding genes, such as lncRNAs [12].
lncRNAs can exhibit similarities to both miRNAs and mRNAs. While lncRNAs share several characteristics with protein-coding RNAs (mRNAs), they lack the open reading frame, exhibit lower sequence conservation, and are expressed at lower levels [13,14]. Based on their loci of origin, lncRNAs can be classified as intergenic/intronic, sense/antisense, bidirectional, or overlapping with protein-coding genes or other ncRNAs [15]. Mechanistically, various lncRNAs function as co-transcriptional regulators of protein-coding genes and play roles in diverse biological and developmental pathways [16]. Studies have shown that approximately 20–30% of lncRNAs can guide specific epigenetic enzymes to their specific region within the genome by physically interacting with lncRNAs and these regions [17]. By binding to chromatin-modifying proteins, lncRNAs can modulate chromatin states, thereby influencing gene expression related to DNA repair and cell adhesion [4,18]. Additionally, by interacting with promoters and transcription factors, they can directly affect the transcription of nearby genes. In cancer cells, these processes can become dysregulated, highlighting the potential role of some lncRNAs in modulating cellular transformation [16].
EMT is considered one of the primary mechanisms of cellular transformation that drives aggressive behavior in advanced cancers. During EMT, epithelial cells acquire mesenchymal traits, reorganize their cytoskeleton, and alter their polarity, transforming into motile, spindle-shaped cells. Key molecular features of EMT include the elevated expression of canonical EMT-transcriptional factors, a cadherin switch from E-cadherin to N-cadherin, and downregulation of the miR-200 family. The miR-200 family has been identified as a potent suppressor of EMT through the translational repression of target mRNAs. Our previous research [19] has indicated that EMT and the downregulation of miR-200 are involved in the development and progression of renal cell carcinoma (RCC), one of the most common urological malignancies with a rising incidence rate [20]. Development of metastases is observed in up to 30% of patients with localized disease, posing significant challenges regarding treatment. Moreover, certain RCC subtypes, such as sarcomatoid renal cell carcinoma (sRCC), are particularly aggressive [21]. Biallelic inactivation of the tumor suppressor gene VHL is the predominant genetic alteration in most sporadic clear cell RCCs (ccRCCs). Consequently, inactivation of VHL leads to the stimulation of EMT activation due to accumulation hypoxia-inducible factors (HIFs) [22,23]. However, the exact relationships between miR-200 signaling pathways and the molecular pathways governing EMT remain complex and not fully understood.
Additionally, various lncRNAs can target specific miRNAs, thereby suppressing or activating their interaction with target mRNAs. This interaction might promote or inhibit EMT and tumor progression. Some lncRNAs targeting the miR-200 family have previously been studied in ccRCC, including MALAT1, GIHCG, etc. (reviewed in [24]). The present study aimed to systematically summarize all lncRNAs that have been functionally validated trough in vitro and in vivo experiments as regulators of miR-200 family expression in various pathological and physiological processes. Additionally, the expression of the identified lncRNAs was analyzed in early and advanced ccRCC, as well as in sRCC, and their levels correlated with the expression of the miR-200 family. The aim was to identify lncRNAs that might also be potential regulators or targets of the miR-200 family in RCC.

2. Materials and Methods

2.1. Patients and Tissue Samples

In our retrospective study, we examined 25 patients diagnosed with renal cell carcinoma, all of whom underwent surgical treatment between 2016 and 2022. The exclusion criteria were as follows: none of the patients had received neoadjuvant therapy, including chemotherapy, radiotherapy, or renal artery embolization prior to surgery. Tumor staging was conducted based on the latest AJCC/UICC TNM staging system for renal tumors [25].
Tumors were graded by two pathologists (JJ and TČ) according to the 2016 edition of the ISUP/WHO pathological grading criteria for renal cell carcinoma [26]. In cases of sRCC, the sarcomatoid component constituted between 30% and 90% of the tumor mass, while the carcinomatous component was ccRCC in all cases of sRCC.
Post-nephrectomy, resection specimens were processed following standard histopathological protocols: fixation in 10% neutral buffered formalin for 24 h, after which representative tissue samples were obtained from both the tumor mass and macroscopically unremarkable renal cortex. These samples were subsequently embedded in paraffin (formalin-fixed paraffin-embedded, FFPE), sectioned into 3–4 µm thick slices, and stained with hematoxylin and eosin for microscopic evaluation.
All slides were subsequently re-examined by a urologic pathology specialist. Patients were divided into three groups: pT1 ISUP/WHO grade II ccRCC (i.e., early ccRCC); pT3 ccRCC with renal vein invasion (i.e., advanced ccRCC); and sRCC.
In the early ccRCC group, representative slides were selected of both the tumor and adjacent non-neoplastic renal cortical tissue. For the sRCC group, slides were chosen that represented the sarcomatous (sRCC-Sa) and the carcinomatous component (sRCC-Ca), as well as the non-neoplastic renal cortical tissue. Tumor cells in all ccRCC and sRCC-Ca cases displayed a characteristic epithelioid morphology, while sRCC-Sa tumor cells showed a distinct spindle-shaped morphology. In advanced ccRCC, representative slides of the tumor center (TC), tumor periphery (TP), renal vein tumor thrombus (VTT), and adjacent non-neoplastic renal cortical tissue were selected. Each type of tumor tissue (early RCC; TC, TP, VTT of advanced ccRCC, sRCC-Ca, and sRCC-Sa) and adjacent non-neoplastic renal cortical tissue was represented by 6 biological replicates (Table S1).
Paraffin blocks corresponding to all slides were retrieved from the archives of the Institute of Pathology, Faculty of Medicine, University of Ljubljana. For molecular analysis, three to five tissue cores (0.6 mm un diameter) were obtained from paraffin blocks: from the TC of both ccRCC (with and without renal vein invasion), the TC of both components of sRCC, the non-neoplastic kidney, TP and VTT of ccRCC with renal vein invasion.

2.2. lncRNA Search

To identify lncRNAs that were potential regulators of the miR-200 family, we performed a search of publications in PubMed using the following key words: “lncRNA & miR-200”, “lncRNA & miR-200a”, “lncRNA & miR-200b”, “lncRNA & miR-200c”, “lncRNA & miR-141”, and “lncRNA & miR-429”. The resulting abstracts were screened for the functionally validated interaction and regulation of the miR-200 family by lncRNAs irrespective of the cell line or disease context. Studies that, based on abstract screening, did not report a functionally validated lncRNA–miR-200 family pair or axis were excluded.

2.3. Database Search for miRNA-lncRNA Interactions

To systematically catalog interactions between the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and lncRNA, we queried three complementary resources that curate RNA–RNA interactions: RNA In-teractome [27], DIANA-LncBase v3 [28], and ENCORI (miRNA–ncRNA module) [29]. Searches were performed for organisms restricted to Homo sapiens and RNA interaction where available. Databases and access dates were as follows: RNA Interactome (http://www.rnainter.org/, accessed on 26 August 2025), DIANA-LncBase v3 (https://diana.e-ce.uth.gr/lncbasev3, accessed on 26 August 2025), and ENCORI miRNA-lncRNA module (https://rnasysu.com/encori/agoClipRNA.php?source=lncRNA, accessed on 26 August 2025). For each miRNA, we retrieved all reported lncRNA targets.
In DIANA-LncBase v3, we retained all reported pairs; in RNA Interactome, we excluded pairs with a score < 0.0001; and in ENCORI, we kept only pairs where the predicted target site overlapped an Ago protein binding site.
We ran three intersection analyses: (i) per-miRNA intersections (lncRNAs present in all three databases for a given miRNA), (ii) within-database pan-miR-200 sets (lncRNAs reported for all five miR-200 family members within the same database), and (iii) a global intersection spanning all databases and all miR-200 family members.

2.4. RNA Isolation from FFPE Tissue Samples

Three to five 0.6 mm punches from FFPE blocks of each representative region were used for the isolation procedure. Additional slides were cut from punched FFPE blocks, HE-stained, and evaluated by pathologist to ensure that accurate regions were punched for isolation. All reagents were from Thermo Fisher Scientific (Austin, TX, USA), except ethanol (Merck KGaA, Darmstadt, Germany) and the xylene (SigmaAldrich; Merck KGaA, Darmstadt, Germany), which was used as a deparaffinization solution. Manual RNA isolation was performed using the MagMAX FFPE DNA/RNA Ultra kit (Thermo Fisher Scientific, Austin, TX, USA) following the manufacturer’s protocol with one modification, which was overnight digestion in protease. The concentration and purity of the isolated RNA were assessed using a NanoDrop-One (ThermoFisher Scientific; Foster City, CA, USA), measuring wavelengths at 230, 260, and 280 nm.
For quality control, amplification of GAPDH (Hs_GAPDH_vb.1_SG, 100 bp, Qiagen) using SYBR Green technology was performed. First, RNA from samples was reverse-transcribed (RT) as described below, and 1 µL of resulting cDNA was used in 10 µL quantitative real-time PCR (qPCR). All samples in this study underwent this initial quality control, and those that would not amplify (Cq < 35) were excluded from further testing.

2.5. Analysis of Expression of miR-200 Family

2.5.1. Reverse Transcription (RT) of miRNAs

The miRCURY LNA RT Kit (Qiagen; Hilden, Germany) was used for RT of miRNAs according to the manufacturer’s protocol. UniSp6 was added as spike-in RNA to measure the success of the RT procedure by its subsequent quantification. RT was performed in 10 µL reaction master mix with 10 ng of RNA in 6.5 µL, 0.5 µL UniSp6 Spike-in 1 µL miRCURY RT Enzyme Mix 10× and 2 µL of miRCURY RT Reaction Buffer 5×. The reaction conditions were as follows: 42 °C for 60 min, then heat inactivation of reverse transcriptase at 95 °C for 5 min, followed by immediate cooling to 4 °C.

2.5.2. Quantitative Real-Time PCR (qPCR)

A pre-designed mixture of specific primers for measuring the expression of the miR-200 family (miR-141-3p, miR-200a-3p, miR-200b-3p, miR-200c-3p, and miR-429) was used in qPCR with SYBR Green. As reference genes (RGs), miR-28, miR-103a-3p, and miR-106a-5p were used, as suggested by other studies [30]. The 10 µL reaction included 3 µL of diluted (1:60) cDNA, 5 µL of miRCURY LNA SYBR GREEN Kit, 1 µL of miRCURY LNA miRNA PCR Primer Assay 10×, and 1 µL of PCR-grade H2O. Rotor Gene Q was used to perform amplification of miRNAs with the following thermal cycling conditions: 95 °C for 2 min, 40 cycles at 95 °C for 10 s, and 56 °C for 1 min; melting curve analysis was performed after amplification to confirm the specificity of amplicons. All qPCR reactions were performed in duplicates. The efficiency of the miR-200 family and RG amplification was obtained from a previous study [19].

2.6. Analysis of Expression of lncRNAs

2.6.1. Reverse Transcription (RT) for lncRNAs

Samples were reversely transcribed using M-MLV Reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, USA) as reported previously [31]. RT was performed by mixing 6 µg of random hexamers and a maximal quantity of RNA and incubated at 65 °C for 10 min. The reaction was followed by adding the RT mix, which included 250 U of M-MLV RT, 10 mM DTT, First Strand Buffer 1×, 1 mM dNTP, 4.5 mM MgCl2 and 4 U RNase inhibitor. The volume of RT reaction was 20 µL, and the reaction was run at 25 °C for 10 min, 37 °C for 60 min, and 70 °C for 15 min.

2.6.2. Quantitative Real-Time PCR (qPCR) and Probes

According to initial quality control with GAPDH, we chose TaqMan probes (Thermo Fisher scientific, Waltham, MA, USA) for analysis of the expression of lncRNAs and RGs by qPCR to obtain amplicons with a length below 100 bp. mRNAs that were found to be suitable for expression analyses in RCC in previous studies including ours [32] were used as reference genes (ACTB, HPRT1, RPL13A, SDHA, and B2M) in expression analysis of lncRNAs. All mRNA qPCR analyses were performed in duplicates using a Quant Studio 7 Pro (Thermo Fisher Scientific; Foster City, CA, USA), with signal collection at the endpoint of each cycle.
In the qPCR reaction, 4.5 µL of diluted cDNA (1.4–42 ng) was used in a 10 µL total reaction volume containing 0.5 µL of TaqMan 20× probe and 5.0 µL of 2× FastStart Essential DNA Probe Master Mix (Roche, Basel, Switzerland). Cycling conditions were 50 °C for 2 min, 95 °C for 10 min (initial denaturation), and 45 cycles of 95 °C for 15 s and at 62 °C for 1 min (annealing/extension).

2.7. Expression of lncRNAs and miR-200 Family in KIRC (ccRCC) from RNA Sequencing Datasets Using the Cancer Genome Atlas

To verify the expression of the analyzed transcripts, we utilized RNA sequencing data from the kidney renal clear cell carcinoma (KIRC) project from The Cancer Genome Atlas (TCGA) (accessed on 9 June 2023). After identifying and removing duplicate samples during preprocessing, 511 unique tumor samples remained, all corresponding to ccRCC. The cBioPortal interactive online database was used to access the data. Read per million (RPM) mapped miRNA isoforms for miRNA experiments and fragments per kilobase of transcript per million mapped reads in the upper quartile (FPKM-UQ) were obtained as normalized gene counts (level 3 data). Data were presented in box plots as RPM and FPKM-UQ for miRNA and lncRNA experiments, respectively. The R programming package was used for statistical analyses of correlations. Unfortunately, no samples of sRCC were identified in the database.

2.8. Statistical Analysis

Results were expressed as relative gene expression using the ΔCq method. At first, all Cqs were corrected for PCR efficiencies for miRNAs and RGs. Second, the average value of Cq was calculated from technical replicates for each biological replicate. Next, the geometric mean of average Cq values for the RGs was subtracted from the average Cq values of the genes of interest (GOIs, e.g., miRNA, lncRNA) to obtain ∆Cq for each biological sample. The results were presented as box plots, where a lower value means higher expression of miRNA or lncRNA. For correlations in our own samples, Spearman rank-order correlation was used; for correlations in TCGA samples, the Pearson correlation coefficient was used. We additionally performed the Mann–Whitney test to analyze differences in the expression of the miR-200 family and lncRNAs between TP, TC, VTT, sRCC-Ca, sRCC-Sa, ccRCC, and non-neoplastic renal cortical tissue. Statistical analysis of data was performed using SPSS version 27 (SPSS Inc., Chicago, IL, USA). Differences were considered significant at p values < 0.05.

3. Results

3.1. Patients and Tissue Samples

In total, we analyzed 42 samples from 25 patients. There were 20 males and 5 females, with a mean age of 62.9 ± 9.6. In early ccRCC, partial nephrectomies were performed in all but one instance. For advanced ccRCC, all patients underwent total nephrectomies, while in the sRCC group, all but one underwent total nephrectomies. In the early ccRCC group, all tumors were classified as pT1a. In the advanced ccRCC group, nine cases were pT3a and one was pT3b. In the sRCC group, tumor stages included pT1a (n = 1), pT2a (n = 1), pT3a (n = 5), and pT4 (n = 1). Detailed information is provided in Table 1. The sampling distribution among patients is presented in Table S1. Morphological features are presented in Figure 1 and Figure 2.

3.2. Indentification of Target lncRNAs

3.2.1. Identified lncRNAs with Potentially Regulatory Function Toward miR-200 Family

Using PubMed, we searched for lncRNAs that could potentially regulate the miR-200 family. We identified 127 lncRNAs that could regulate any of the miR-200 family members. The list of all identified lncRNAs with target miRNA of the miR-200 family is summarized in Table S2. Among these 127 lncRNAs, we searched for predesigned TaqMan probes with a Small RNA assay to perform validation on RCC samples. We identified 31 such lncRNAs and performed expression analysis in our cohort. A detailed list of these 31 lncRNAs is summarized in Table S3 and in Table 2.

3.2.2. miRNA-lncRNA Interactions Identified from Cross-Database Search

Our cross-database search returned differing numbers of lncRNA targets for each miR-200 family member. The numbers of lncRNA targets are presented in Table 3. Detailed results with specific lncRNAs are presented in Tables S4–S6.
Intersecting all three databases per miRNA yields the results shown in Table 4. The three-way intersection contained two lncRNAs for miR-200a and three for each of the remaining miR-200 members.
We also performed within-database miR-200 family intersections to identify lncRNAs reported for all five miR-200 members within a single database. This yielded 15 lncRNAs in DIANA-LncBase v3, 6 in ENCORI, and 22 in RNA Interactome (Table 5).
Interestingly, MALAT1 was the only lncRNA common both to all miR-200 family members and to all three databases (DIANA-LncBase v3, ENCORI, and RNA Interactome).

3.3. Expression of miR-200 Family, Their Regulatory lncRNAs, and Correlation Between Them in ccRCC and sRCC

3.3.1. Expression of miR-200 Family in Our Cohort of Patients

We observed consistent downregulation of all members of the miR-200 family compared to the non-neoplastic renal cortex, and this downregulation was observed in all tumor samples, including early ccRCC, TP, VTT, and TC of advanced ccRCC and the carcinomatous and sarcomatoid component of sRCC. The results are summarized in Figure 3. The statistical analysis of the expression of the miR-200 family between different groups of samples was limited by the small sample size within each tested group (n = 6); therefore, the results are presented in Table S7.

3.3.2. Expression of lncRNAs in Our Cohort of Patients

Out of 31 tested lncRNAs, 13 were expressed in all tested samples. Six lncRNAs were expressed in most samples (38 to 41), five in over half of the samples (28 to 35), and four lncRNAs in a smaller number of samples (13 to 19). One lncRNA previously linked to miR-200 regulation was below the detection limit (MAGI1-IT1); two miRNAs were omitted from further analysis due to article retractions (TUNCAR and UCA1). The results are summarized in Figure 4. The statistical analysis of the expression of 31 lncRNAs between different groups of samples is shown solely in Table S7, due to the small sample size in each tested group (n = 6).

3.3.3. Correlation Between Expression of miR-200 Family and Expression of Potentially Regulatory lncRNAs

Of the 31 analyzed lncRNAs, the expression of 17 lncRNAs showed a statistically significant correlation with the expression of at least one member of the miR-200 family. Notably, the expression of two miRNAs, miR-200b and miR-141, correlated with the expression of more than half of these lncRNAs: miR-200b correlated with the expression of 16 lncRNAs, and miR-141 correlated with the expression of 11 lncRNAs. In contrast, the expression of the other three miRNAs, miR-200a, miR-200c, and miR-429, each correlated with fewer lncRNAs: four, four, and seven lncRNAs, respectively.
Conversely, the expression of six lncRNAs correlated with the expression of only a single member of the miR-200 family—miR-200b in five cases and miR-200a in one. The expression of four lncRNAs correlated with the expression of two members of the miR-200 family, the expression of three lncRNAs correlated with the expression of three members of the miR-200 family, and the expression of one lncRNA correlated with the expression of four members of the miR-200 family. Finally, the expression of three lncRNAs, namely, LINC00467, MALAT1, and OIP5-AS1, correlated with the expression of all five members of the miR-200 family. The results are summarized in Table S8 and Figure 5.

3.4. Expression of miR-200 Family, Their Potentially Regulatory lncRNAs, and Correlation Between Them in KIRC from TCGA

3.4.1. Expression of miR-200 Family in KIRC Samples from TCGA

When analyzing the number of normalized transcripts of the miR-200 family in carcinomatous tissue compared to non-carcinomatous tissue of KIRC, we observed a consistently smaller number of transcripts in carcinomatous tissue compared to non-carcinomatous tissue. The results are in accordance with those observed in our samples and are summarized in Figure 6.

3.4.2. Expression of lncRNAs in KIRC Samples from TCGA

When analyzing the expression of all 127 identified lncRNAs with regulatory function toward any of the miR-200 family members using KIRC and TCGA, we observed that 86 lncRNAs were expressed in carcinomatous and non-carcinomatous tissue. Of 31 lncRNAs quantified using qPCRs on our samples, transcripts were detected/annotated for 24 lncRNAs in carcinomatous and non-carcinomatous KIRC samples. Combining the results of KIRC samples from TCGA and our samples, we confirmed the expression of 92 identified lncRNAs in renal/kidney tissue.
We further analyzed whether the expression of LINC00467, MALAT1, and OIP5-AS1 was similar to that observed in our cohort of samples, and we observed a similar trend of expression.
The results are summarized in Tables S9 and S10 and Figure 7.

3.4.3. Correlation Between miR-200 Family and Potentially Regulatory lncRNAs

We have calculated the correlations between the miR-200 family and 86 expressed lncRNAs in carcinoma and non-carcinoma tissue in KIRC. The expression of five lncRNAs, namely, CRNDE, LINC00365, MSC-AS1, SFTA1P, and TRAF3IP2-AS1, were in correlation with the expression of all members of the miR-200 family.
To validate the findings obtained from our cohort, we performed an additional correlation analysis using tumor and morphologically normal samples from KIRC, applying statistical evaluation with SPSS. This analysis confirmed a weak positive correlation between the expression of the miR-200 family and LINC00467, a very weak positive correlation between expression of OIP5-AS1 and expression of miR-200a/b/c, and a very weak negative correlation between expression of MALAT1 and expression of miR-200c.
The results are summarized in Table S11.

4. Discussion

miRNAs are encoded as inter- or intragenic units. Intergenic miRNAs are encoded as single genes or as clusters, leading to co-regulation and co-transcription of certain clusters [89], and their transcription in the form of independent units, as a monocistronic, bicistronic or polycistronic primary transcript [90]. Although the functional roles of miRNAs vary, their primary mechanism of action in mammals is believed to involve the inhibition of mRNA translation by base-pairing with the 3′ UTR of target mRNAs. Each miRNA is predicted to have as many as 200 target genes, and it is also common for mRNA to be regulated by multiple miRNAs. This cooperative action, either through multiplicity (multiple identical miRNAs) or through cooperativity (different miRNAs), enhances the efficiency of translational inhibition and increases the specificity of miRNAs. Moreover, combinatorial control of gene expression may arise from a set of coordinately expressed miRNAs [91]. The miR-200 family comprises five members: miR-200a, miR-200b, miR-200c, miR-141, and miR-429. This family can be classified into two categories based on chromosomal location: Cluster I includes miR-200a, miR-200b, and miR-429, while Cluster II consists of miR-141 and miR-200c. Additionally, a classification based on seed sequences that bind to the 3′ UTR of target genes further divides the family: Cluster I includes miR-200b, miR-200c, and miR-429, whereas Cluster II comprises miR-200a and miR-141. It is hypothesized that members of the same miRNA family are distributed across different genomic locations, which may enhance the spatial, temporal, and tissue-specific regulation of target gene expression. This regulation is further influenced by histone modifications [6,7]. Beyond miRNAs, other ncRNAs play crucial roles in the pathogenesis of cancer and various diseases and can also regulate miRNA expression [7]. In our previous research, we summarized the lncRNAs that function as competitive endogenous RNAs, thereby modulating miR-200 expression and contributing to the metastatic phenotype in different cancers [9]. In the present study, we identified three lncRNAs, MALAT1, OIP5-AS1, and LINC00467, as potential regulators of miR-200 family expression in ccRCC.
Several studies have demonstrated the upregulation of long intergenic non-coding RNA 467 (LINC00467) across various cancer types, suggesting its potential oncogenic role (reviewed in [92]). Current data indicates that its primary mode of action involves functioning as a ceRNA, effectively sponging multiple miRNAs. In urological malignancies, LINC00467 has been found to be upregulated in bladder carcinoma, where it regulates tumor cell proliferation and invasiveness through the NF-κB signaling pathway. Gao et al. [43] showed that LINC00467 negatively regulates the expression of miR-200a in glioma cell lines, while promoting E2F3 expression. To the best of our knowledge, our study is the first to suggest the role of the entire miR-200 family as an indirect or direct target of LINC00467 in RCC.
Analysis of various carcinomas shows that OIP5 antisense transcript 1 (OIP5-AS1) is implicated in the oncogenesis of these carcinomas and that OIP5 is highly expressed in neural tissues [93]. Its role appears to be contradictory, with some studies reporting its tumor-suppressive function (reviewed in [94]). Additionally, Liu et al. [95] observed a downregulation of OIP5-AS1 in endometrial carcinoma and identified miR-200c as its target. In the context of urological malignancies, OIP5-AS1 is upregulated and functions as an oncogene, correlating with poorer survival outcomes [96,97]. While Zhang et al. [98] demonstrated an oncogenic role of OIP5-AS1 in bladder carcinoma and identified miR-217 as a direct target, Feraydoon et al. [99] reported a tumor-suppressive role of this transcript. Interestingly, a study by Fu et al. [100] showed that by binding to miR-30c-5p in diabetic nephropathy, OIP5-AS1 induces EMT and renal fibrosis, highlighting the diverse effects of lncRNAs under physiological and pathological conditions.
In various cancer types, there is increasing evidence to suggest that MALAT1 is abnormally expressed, suggesting that MALAT1 functions as an oncogene through multiple biological mechanisms, including its role as a ceRNA that binds to various miRNAs [101,102]. In non-small cell lung carcinoma, MALAT1 facilitates disease progression by modulating the miR-200a-3p/PDL1 axis [103]. The interplay between MALAT1 and members of the miR-200 family has also been demonstrated in endometrioid endometrial carcinoma [104], anaplastic thyroid carcinoma [105], and hepatocellular carcinoma [106]. In RCC tissues, MALAT1 is highly expressed, and acts as a sponge for the miR-200 family [54], leading to the induction of zinc finger E-box-binding homeobox 2 (ZEB2). Furthermore, Huang et al. [107] provided evidence that MALAT1 can sponge miR-205, facilitating proliferation and invasion in RCC. These results emphasize the diverse pathways through which MALAT1 can contribute to the progression of RCC.
Our analysis revealed a positive correlation between the expression of the miR-200 family and investigated lncRNAs. There are several potential explanations that may account for this observation. Expression profiling of many ncRNAs in various normal and diseased tissues has revealed unique spatial and temporal expression patterns [108]. Many ncRNAs exhibit tissue-specific and/or cell type-specific expression [109]. Given the diversity of genes and expression patterns, it is reasonable to propose that each cell type might have a distinct miRNA expression profile at different developmental stages. Therefore, it is not surprising that our analysis revealed an inverse correlation, in contrast with the patterns observed between lncRNAs and the miR-200 family in in vitro and in vivo ‘’non-RCC’’ studies.
Another explanation for the observed positive correlation could lie in the nature of lncRNAs. Large intergenic ncRNAs (lincRNAs) tend to be modestly conserved and can both up- and downregulate the expression of hundreds of genes, including miRNAs. Additionally, about 25% of enhancers co-localize with RNAPII sites, suggesting that some enhancer RNAs (eRNAs) are also transcribed [110] and play key roles in epigenetic gene regulation in mammalian cells. Generally, lncRNAs have been implicated in gene-regulatory roles, influencing nearly every step in the life cycle of genes, including transcription, mRNA splicing, and RNA decay and translation [108]. Therefore, a function observed in one cell type (e.g., non-RCC) may not necessarily be conserved or established in another type (e.g., RCC).
Finally, a key distinction between epithelial-derived carcinomas and ccRCC is that ccRCC originates from the malignant transformation of proximal tubular cells [111], which embryologically originate from mesenchymal tissue, specifically the metanephric mesenchyme [112]. Notably, both ccRCC and normal proximal tubular cells can co-express epithelial and mesenchymal cadherins [19,113,114]. This may partially explain the observed differences in the expression trends of the investigated EMT markers and their regulators compared to carcinomas derived from epithelial tissue.
The observed discrepancies observed between our samples and those from The Cancer Genome Atlas (TCGA) can be attributed to at least two factors. First, there is a difference in the utilized samples. The TCGA dataset includes samples from various projects, employing different isolation methods from either FFPE or fresh-frozen tissue, and encompasses ccRCC samples of different stages and grades. In contrast, our samples include not only ccRCC but also sarcomatoid RCC (sRCC), along with vascular tumor thrombus (VTT) samples from ccRCC. Second, we employed qPCR, while TCGA data are based on next-generation sequencing (NGS). Both approaches have inherent differences related to the targets used. Many commercial NGS platforms have emerged, achieving base accuracy rates as high as 99.99% due to the vast amount of information they process. However, this can create a bottleneck in analysis, as bioinformatics expertise is required to interpret the data accurately. Additionally, potential biases can occur, such as PCR bias during library preparation or sequencing; high GC content or secondary structure fragments are less likely to be amplified, and it can be challenging to determine whether the number of repetitions reflects the actual sample or is a deviation caused by PCR. In contrast, qPCR involves reverse transcription of RNA into complementary DNA (cDNA), followed by amplification using real-time fluorescence. There is a linear relationship between the cycle quantitation (Cq value) of each template and the logarithm of the starting copy number of the template. This quantification process is highly automated, and the quality standards are relatively stable, ensuring the accuracy of the results. Consequently, qPCR is considered an established method that is both sensitive and specific [115]. In parallel, data from multiple databases—including DIANA, ENCORI, and RNA Interactome—support the involvement of certain lncRNAs (e.g., MALAT1, OIP5-AS1) as putative regulators or targets of the miR-200 family in RCC.
However, our study has several limitations. First, we did not perform functional validation (e.g., gain- and loss-of-function assays, in vitro and in vivo experiments) for lncRNAs whose expression correlated with at least one member of the miR-200 family. While some of these lncRNAs have already been previously validated in other cancer types, they have not yet been validated in RCC cell lines. Second, the relatively smaller sample size, resulting from the analysis of a larger number of lncRNA transcripts (n = 31) may have limited the statistical power of our findings. However, this limitation could be partially mitigated by incorporating KIRC data from the TCGA cohort. Finally, further research is needed to explore the clinical utility of the miR-200 family, including multi-center validation studies.

5. Conclusions

ncRNAs primarily serve regulatory functions, do not encode proteins, and are represented by a diverse class of RNA molecules. The miR-200 family is a well-known inhibitor of EMT. Our findings suggest that, in RCC, the expression of the miR-200 family might be at least partially in correlation with the expression of certain lncRNAs. Thus, investigating co-expression patterns between different classes of ncRNAs in RCC (e.g., between miR-200 family and lncRNAs) may serve as a starting point and opportunity for the development of experimental and cell-line based research settings to confirm interaction between certain lncRNAs and the miR-200 family in RCC as well. Such investigations might provide deeper insights to aid our understanding of the progression of RCC to the more aggressive form of the disease that occurs in up to 30% of patients (e.g., the metastatic form and sRCC).

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/cancers17193123/s1, Table S1: The scheme of sampling distribution among patients; Table S2: The list of all identified lncRNAs with target miRNA of the miR-200 family using PubMed; Table S3: TaqMan probes used for expression analysis; Table S4: miRNA–lncRNA pairs retrieved from DIANA-LncBase v3 database for the miR-200 family; Table S5: miRNA–lncRNA pairs retrieved from ENCORI database for the miR-200 family; Table S6: miRNA–lncRNA pairs retrieved from RNA Interactome database for the miR-200 family; Table S7: Summary of statistically significant miR-200 family members and their potentially regulatory/target lncRNAs in RCC; Table S8: Spearman correlations of analyzed lncRNA and miR-200 family RNAs; Table S9: Expression of selected lncRNA in normal kidney tissue from TCGA database; Table S10: Expression of selected lncRNA in KIRC tumor samples from TCGA database; Table S11: Correlations between lncRNAs and miR-200 family miRNAs in TCGA normal and tumor samples.

Author Contributions

Conceptualization, E.B. and J.J.; methodology, T.Č., E.B., and N.H.; software, N.H.; validation, N.H. and E.B.; formal analysis, T.Č. and E.B.; investigation, E.B.; resources, N.H.; data curation, E.B. and T.Č.; writing—original draft preparation, T.Č.; writing—review and editing, E.B. and J.J.; visualization, E.B.; supervision, E.B. and J.J.; project administration, J.J.; funding acquisition, J.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Slovenian Research and Innovation Agency, grant number P3-0054.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the National Medical Ethics Committee Slovenia (protocol code 0120-96/2020/3, date of approval: 1 April 2020).

Informed Consent Statement

Patient consent was waived for the following reason: as indicated in the approval document, this study is retrospective and observational, utilizing tissue samples obtained during routine diagnostic or therapeutic procedures, specifically excision or resection. Sufficient tissue was available for both routine analysis and research purposes, and additional samples can still be accessed for future analyses. Our State Ethical Committee does not mandate informed consent for patients in such studies. However, informed consent was obtained prior to the routine procedures.

Data Availability Statement

All data generated or analyzed during this study are included in the article; further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ccRCCclear cell RCC
EMTepithelial–mesenchymal transition
FFPEformalin-fixed paraffin-embedded
FPKM-UQfragments per kilobase of transcript per million mapped reads—upper quartile
GOIgene of interest
HIFhypoxia-inducible factor
ISUPInternational Society of Urologic Pathologists
KIRCkidney renal clear cell carcinoma
LINC00467large intergenic non-coding RNA 00467
lncRNAlong non-coding RNA
MALAT1metastasis-associated lung adenocarcinoma transcript 1
miRNAmicroRNA
mRNAmessenger RNA
ncRNAnon-coding RNA
OIP5-AS1OPA-interacting protein 5 antisense transcript 1
Qpcrquantitative polymerase chain reaction
RCCrenal cell carcinoma
RNAribonucleic acid
RGreference gene
RPMreads per million
RTreverse transcriptase/transcription
sRCCsarcomatoid RCC
TCtumor center
TCGAThe Cancer Genome Atlas
TNMtumor node metastasis
TPtumor periphery
WHOWorld Health Organization
VTTvenous tumor thrombus

References

  1. Diamantopoulos, M.A.; Tsiakanikas, P.; Scorilas, A. Non-coding RNAs: The riddle of the transcriptome and their perspectives in cancer. Ann. Transl. Med. 2018, 6, 241. [Google Scholar] [CrossRef] [PubMed]
  2. Hassler, M.R.; Egger, G. Epigenomics of cancer—Emerging new concepts. Biochimie 2012, 94, 2219–2230. [Google Scholar] [CrossRef]
  3. Mercer, T.R.; Mattick, J.S. Structure and function of long noncoding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol. 2013, 20, 300–307. [Google Scholar] [CrossRef]
  4. Lee, C.; Kikyo, N. Strategies to identify long noncoding RNAs involved in gene regulation. Cell Biosci. 2012, 2, 37. [Google Scholar] [CrossRef] [PubMed]
  5. Kitagawa, M.; Kitagawa, K.; Kotake, Y.; Niida, H.; Ohhata, T. Cell cycle regulation by long non-coding RNAs. Cell. Mol. Life Sci. 2013, 70, 4785–4794. [Google Scholar] [CrossRef] [PubMed]
  6. Klicka, K.; Grzywa, T.M.; Mielniczuk, A.; Klinke, A.; Włodarski, P.K. The role of miR-200 family in the regulation of hallmarks of cancer. Front. Oncol. 2022, 12, 965231. [Google Scholar] [CrossRef]
  7. Sundararajan, V.; Burk, U.C.; Bajdak-Rusinek, K. Revisiting the miR-200 Family: A Clan of Five Siblings with Essential Roles in Development and Disease. Biomolecules 2022, 12, 781. [Google Scholar] [CrossRef]
  8. Gao, Y.; Takenaka, K.; Xu, S.-M.; Cheng, Y.; Janitz, M. Recent advances in investigation of circRNA/lncRNA-miRNA-mRNA networks through RNA sequencing data analysis. Brief. Funct. Genom. 2025, 24, elaf005. [Google Scholar] [CrossRef]
  9. Uhan, S.; Hauptman, N. Metastatic EMT Phenotype Is Governed by MicroRNA-200-Mediated Competing Endogenous RNA Networks. Cells 2021, 11, 73. [Google Scholar] [CrossRef]
  10. Zhang, L.; Meng, X.; Zhu, X.W.; Yang, D.C.; Chen, R.; Jiang, Y.; Xu, T. Long non-coding RNAs in Oral squamous cell carcinoma: Biologic function, mechanisms and clinical implications. Mol. Cancer 2019, 18, 102. [Google Scholar] [CrossRef]
  11. Jansson, M.D.; Lund, A.H. MicroRNA and cancer. Mol. Oncol. 2012, 6, 590–610. [Google Scholar] [CrossRef] [PubMed]
  12. Kim, Y.K.; Kim, V.N. Processing of intronic microRNAs. EMBO J. 2007, 26, 775–783. [Google Scholar] [CrossRef]
  13. Guttman, M.; Amit, I.; Garber, M.; French, C.; Lin, M.F.; Feldser, D.; Huarte, M.; Zuk, O.; Carey, B.W.; Cassady, J.P.; et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009, 458, 223–227. [Google Scholar] [CrossRef]
  14. Djebali, S.; Davis, C.A.; Merkel, A.; Dobin, A.; Lassmann, T.; Mortazavi, A.; Tanzer, A.; Lagarde, J.; Lin, W.; Schlesinger, F.; et al. Landscape of transcription in human cells. Nature 2012, 489, 101–108. [Google Scholar] [CrossRef]
  15. Li, X.; Wu, Z.; Fu, X.; Han, W. Long Noncoding RNAs: Insights from Biological Features and Functions to Diseases. Med. Res. Rev. 2013, 33, 517–553. [Google Scholar] [CrossRef] [PubMed]
  16. Gibb, E.A.; Brown, C.J.; Lam, W.L. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 2011, 10, 38. [Google Scholar] [CrossRef]
  17. Karapetyan, A.R.; Buiting, C.; Kuiper, R.A.; Coolen, M.W. Regulatory Roles for Long ncRNA and mRNA. Cancers 2013, 5, 462–490. [Google Scholar] [CrossRef] [PubMed]
  18. Kanduri, C. Long noncoding RNAs: Lessons from genomic imprinting—PubMed. Biochim. Biophys. Acta 2016, 1859, 102–111. [Google Scholar] [CrossRef]
  19. Cugura, T.; Bostjancic, E.; Uhan, S.; Hauptman, N.; Jeruc, J. Epithelial-mesenchymal transition associated markers in sarcomatoid transformation of clear cell renal cell carcinoma. Exp. Mol. Pathol. 2024, 138, 104909. [Google Scholar] [CrossRef]
  20. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
  21. Bukavina, L.; Bensalah, K.; Bray, F.; Carlo, M.; Challacombe, B.; Karam, J.A.; Kassouf, W.; Mitchell, T.; Montironi, R.; O’Brien, T.; et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur. Urol. 2022, 82, 529–542. [Google Scholar] [CrossRef]
  22. Hapke, R.Y.; Haake, S.M. Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Lett. 2020, 487, 10–20. [Google Scholar] [CrossRef]
  23. Myszczyszyn, A.; Czarnecka, A.M.; Matak, D.; Szymanski, L.; Lian, F.; Kornakiewicz, A.; Bartnik, E.; Kukwa, W.; Kieda, C.; Szczylik, C. The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev. Rep. 2015, 11, 919–943. [Google Scholar] [CrossRef]
  24. Barth, D.A.; Drula, R.; Ott, L.; Fabris, L.; Slaby, O.; Calin, G.A.; Pichler, M. Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers. Front. Cell Dev. Biol. 2020, 8, 828. [Google Scholar] [CrossRef]
  25. Amin, M.B.; Edge, S.B.; Greene, F.L.; American Joint Committee on Cancer. AJCC Cancer Staging Manual, 8th ed.; Springer: New York, NY, USA, 2017; pp. 17, 1032. [Google Scholar]
  26. Moch, H.; Amin, M.B.; Berney, D.M.; Comperat, E.M.; Gill, A.J.; Hartmann, A.; Menon, S.; Raspollini, M.R.; Rubin, M.A.; Srigley, J.R.; et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2022, 82, 458–468. [Google Scholar] [CrossRef]
  27. Kang, J.; Tang, Q.; He, J.; Li, L.; Yang, N.; Yu, S.; Wang, M.; Zhang, Y.; Lin, J.; Cui, T.; et al. RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility. Nucleic Acids Res. 2022, 50, D326–D332. [Google Scholar] [CrossRef]
  28. Karagkouni, D.; Paraskevopoulou, M.D.; Tastsoglou, S.; Skoufos, G.; Karavangeli, A.; Pierros, V.; Zacharopoulou, E.; Hatzigeorgiou, A.G. DIANA-LncBase v3: Indexing experimentally supported miRNA targets on non-coding transcripts. Nucleic Acids Res. 2020, 48, D101–D110. [Google Scholar] [CrossRef]
  29. Li, J.H.; Liu, S.; Zhou, H.; Qu, L.H.; Yang, J.H. starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014, 42, D92–D97. [Google Scholar] [CrossRef] [PubMed]
  30. Wotschofsky, Z.; Meyer, H.A.; Jung, M.; Fendler, A.; Wagner, I.; Stephan, C.; Busch, J.; Erbersdobler, A.; Disch, A.C.; Mollenkopf, H.J.; et al. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal. Biochem. 2011, 417, 233–241. [Google Scholar] [CrossRef] [PubMed]
  31. Nardon, E.; Donada, M.; Bonin, S.; Dotti, I.; Stanta, G. Higher random oligo concentration improves reverse transcription yield of cDNA from bioptic tissues and quantitative RT-PCR reliability. Exp. Mol. Pathol. 2009, 87, 146–151. [Google Scholar] [CrossRef] [PubMed]
  32. Glenn, S.T.; Jones, C.A.; Liang, P.; Kaushik, D.; Gross, K.W.; Kim, H.L. Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques 2007, 43, 633–642, 647. [Google Scholar] [CrossRef]
  33. Xu, B.; Qin, T.; Yu, J.; Giordano, T.J.; Sartor, M.A.; Koenig, R.J. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma. J. Biol. Chem. 2020, 295, 8834–8845. [Google Scholar] [CrossRef]
  34. Wu, X.; Fan, Y.; Liu, Y.; Shen, B.; Lu, H.; Ma, H. Long Non-Coding RNA CCAT2 Promotes the Development of Esophageal Squamous Cell Carcinoma by Inhibiting miR-200b to Upregulate the IGF2BP2/TK1 Axis. Front. Oncol. 2021, 11, 680642. [Google Scholar] [CrossRef]
  35. Ayeldeen, G.; Shaker, O.G.; Amer, E.; Zaafan, M.A.; Herzalla, M.R.; Keshk, M.A.; Abdelhamid, A.M. The Impact of lncRNA-GAS5/miRNA-200/ACE2 Molecular Pathway on the Severity of COVID-19. Curr. Med. Chem. 2024, 31, 1142–1151. [Google Scholar] [CrossRef]
  36. Amicone, L.; Marchetti, A.; Cicchini, C. The lncRNA HOTAIR: A pleiotropic regulator of epithelial cell plasticity. J. Exp. Clin. Cancer Res. 2023, 42, 147. [Google Scholar] [CrossRef]
  37. Chiyomaru, T.; Fukuhara, S.; Saini, S.; Majid, S.; Deng, G.; Shahryari, V.; Chang, I.; Tanaka, Y.; Enokida, H.; Nakagawa, M.; et al. Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J. Biol. Chem. 2014, 289, 12550–12565. [Google Scholar] [CrossRef] [PubMed]
  38. Bossaghzadeh, F.; Hajjari, M.; Sheikhi, A.; Salahshourifar, I.; Irani, S. HOTAIR Induces the Downregulation of miR-200 Family Members in Gastric Cancer Cell Lines. Iran. Biomed. J. 2022, 26, 77–84. [Google Scholar] [CrossRef] [PubMed]
  39. Yang, Q.; Li, X.; Zhou, Y.; Fu, W.; Wang, J.; Wei, Q. A LINC00341-mediated regulatory pathway supports chondrocyte survival and may prevent osteoarthritis progression. J. Cell. Biochem. 2019, 120, 10812–10820. [Google Scholar] [CrossRef]
  40. Wang, S.Z.; Jia, J.; Chen, C.H. lncRNA-KCNQ1OT1: A Potential Target in Exosomes Derived from Adipose-Derived Stem Cells for the Treatment of Osteoporosis. Stem Cells Int. 2021, 2021, 7690006. [Google Scholar] [CrossRef] [PubMed]
  41. Yu, S.; Yu, M.; He, X.; Wen, L.; Bu, Z.; Feng, J. KCNQ1OT1 promotes autophagy by regulating miR-200a/FOXO3/ATG7 pathway in cerebral ischemic stroke. Aging Cell 2019, 18, e12940. [Google Scholar] [CrossRef]
  42. Huang, W.; Chen, J.; Xu, E.; Zhu, T.; Cai, X. KCNQ1OT1 mediates keratinocyte migration to promote skin wound healing through the miR-200b-3p/SERP1 axis. Burns 2023, 49, 415–424. [Google Scholar] [CrossRef]
  43. Gao, S.; Duan, H.; An, D.; Yi, X.; Li, J.; Liao, C. Knockdown of long non-coding RNA LINC00467 inhibits glioma cell progression via modulation of E2F3 targeted by miR-200a. Cell Cycle 2020, 19, 2040–2053. [Google Scholar] [CrossRef]
  44. Yu, M.; Yi, B.; Zhou, W.; Gong, W.; Li, G.; Yu, S. Linc00475 promotes the progression of glioma by regulating the miR-141-3p/YAP1 axis. J. Cell Mol. Med. 2020, 25, 463–472. [Google Scholar] [CrossRef]
  45. Hang, Q.; Lu, J.; Zuo, L.; Liu, M. Linc00641 promotes the progression of gastric carcinoma by modulating the miR-429/Notch-1 axis. Aging 2021, 13, 8497–8509. [Google Scholar] [CrossRef] [PubMed]
  46. Pan, J.; Zang, Y. LINC00667 Promotes Progression of Esophageal Cancer Cells by Regulating miR-200b-3p/SLC2A3 Axis. Dig. Dis. Sci. 2022, 67, 2936–2947. [Google Scholar] [CrossRef]
  47. Liu, P.; Chen, S.; Huang, Y.; Xu, S.; Song, H.; Zhang, W.; Sun, N. LINC00667 promotes Wilms’ tumor metastasis and stemness by sponging miR-200b/c/429 family to regulate IKK-β. Cell Biol. Int. 2020, 44, 1382–1393. [Google Scholar] [CrossRef] [PubMed]
  48. Li, J.; Kang, J.; Liu, W.; Liu, J.; Pan, G.; Mao, A.; Zhang, Q.; Lu, J.; Ding, J.; Li, H. Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2 axis—PubMed. Eur. J. Histochem. 2022, 66, 3529. [Google Scholar] [CrossRef]
  49. Li, J.; Guan, C.; Hu, Z.; Liu, L.; Su, Z.; Kang, P.; Jiang, X.; Cui, Y. Yin Yang 1-induced LINC00667 up-regulates pyruvate dehydrogenase kinase 1 to promote proliferation, migration and invasion of cholangiocarcinoma cells by sponging miR-200c-3p. Hum. Cell 2021, 34, 187–200. [Google Scholar] [CrossRef] [PubMed]
  50. Bi, M.; Zheng, L.; Chen, L.; He, J.; Yuan, C.; Ma, P.; Zhao, Y.; Hu, F.; Tang, W.; Sheng, M. ln RNA LINC01234 promotes triple-negative breast cancer progression through regulating the miR-429/SYNJ1 axis. Am. J. Transl. Res. 2021, 13, 11399–11412. [Google Scholar]
  51. Han, Z.; Shi, L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem. Biophys. Res. Commun. 2018, 495, 947–953. [Google Scholar] [CrossRef]
  52. Li, D.; Wang, J.; Zhang, M.; Hu, X.; She, J.; Qiu, X.; Zhang, X.; Xu, L.; Liu, Y.; Qin, S. LncRNA MAGI2-AS3 Is Regulated by BRD4 and Promotes Gastric Cancer Progression via Maintaining ZEB1 Overexpression by Sponging miR-141/200a. Mol. Ther. Nucleic Acids 2020, 19, 109–123. [Google Scholar] [CrossRef] [PubMed]
  53. Jiang, L.T.; Wan, C.H.; Guo, Q.H.; Yang, S.J.; Wu, J.D.; Cai, J. Long Noncoding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Renal Cell Carcinoma Progression via Sponging miRNA-429. Med. Sci. Monit. 2018, 24, 1794–1801. [Google Scholar] [CrossRef] [PubMed]
  54. Xiao, H.; Tang, K.; Liu, P.; Chen, K.; Hu, J.; Zeng, J.; Xiao, W.; Yu, G.; Yao, W.; Zhou, H.; et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. Oncotarget 2015, 6, 38005–38015. [Google Scholar] [CrossRef] [PubMed]
  55. Feng, C.; Zhao, Y.; Li, Y.; Zhang, T.; Ma, Y.; Liu, Y. LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge. Arch. Bronconeumol. (Engl. Ed.) 2019, 55, 627–633. [Google Scholar] [CrossRef]
  56. Dong, S.; Ma, M.; Li, M.; Guo, Y.; Zuo, X.; Gu, X.; Zhang, M.; Shi, Y. LncRNA MEG3 regulates breast cancer proliferation and apoptosis through miR-141-3p/RBMS3 axis. Genomics 2021, 113, 1689–1704. [Google Scholar] [CrossRef] [PubMed]
  57. Sha, M.; Lin, M.; Wang, J.; Ye, J.; Xu, J.; Xu, N.; Huang, J. Long non-coding RNA MIAT promotes gastric cancer growth and metastasis through regulation of miR-141/DDX5 pathway. J. Exp. Clin. Cancer Res. 2018, 37, 58. [Google Scholar] [CrossRef]
  58. Ji, Q.; Zhu, J.; Fang, C.L.; Jin, H.; Zhan, D.P.; Huang, J. Down-regulation of MIAT suppresses osteosarcoma progression by acting as a ceRNA for miR-141-3p to regulate SIX1-mediated PI3K/AKT pathway. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 2218–2228. [Google Scholar] [CrossRef]
  59. Zhang, L.; Li, C.; Su, X.; Zhang, L.; Li, C.; Su, X. Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers. J. Exp. Clin. Cancer Res. 2020, 39, 271. [Google Scholar] [CrossRef]
  60. Cui, Z.; An, X.; Li, J.; Liu, Q.; Liu, W. LncRNA MIR22HG negatively regulates miR-141-3p to enhance DAPK1 expression and inhibits endometrial carcinoma cells proliferation. Biomed. Pharmacother. 2018, 104, 223–228. [Google Scholar] [CrossRef]
  61. Cao, J.; Jiang, P.; Jiang, S.; Zhao, Y.; Jiang, X.; Zhou, C.; Li, J.; Yang, K. Long non-coding RNA MIR22HG impedes the progression of anaplastic thyroid carcinoma via targeting miR-141-3p/PTEN/AKT axis. Endokrynol. Pol. 2025, 76, 385–396. [Google Scholar] [CrossRef]
  62. Li, L.; Ye, K.; Wang, D. Upregulation of HTRA1 mediated by the lncRNA NEAT1/miR-141-3p axis contributes to endometriosis development through activating NLRP3 inflammasome-mediated pyroptotic cell death and cellular inflammation. Vitr. Cell. Dev. Biol. Anim. 2023, 59, 166–178. [Google Scholar] [CrossRef] [PubMed]
  63. Zhou, D.; Gu, J.; Wang, Y.; Wu, H.; Cheng, W.; Wang, Q.; Zheng, G.; Wang, X. Long non-coding RNA NEAT1 transported by extracellular vesicles contributes to breast cancer development by sponging microRNA-141-3p and regulating KLF12. Cell Biosci. 2021, 11, 68. [Google Scholar] [CrossRef]
  64. Zhou, W.J.; Wang, H.Y.; Zhang, J.; Dai, H.Y.; Yao, Z.X.; Zheng, Z.; Meng-Yan, S.; Wu, K. NEAT1/miR-200b-3p/SMAD2 axis promotes progression of melanoma. Aging 2020, 12, 22759–22775. [Google Scholar] [CrossRef] [PubMed]
  65. Liu, Y.; Wang, Y.; Cui, L.; Li, R.; Xiao, D. LncRNA OIP5-AS1 suppresses lung adenocarcinoma progression and modulates macrophage polarization through the miR-429/DOCK4 regulatory axis. Front. Pharmacol. 2025, 16, 1569644. [Google Scholar] [CrossRef] [PubMed]
  66. Wu, L.; Liu, Y.; Guo, C.; Shao, Y. LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. Cancer Cell Int. 2020, 20, 296. [Google Scholar] [CrossRef]
  67. Xiao, L.; Yuan, W.; Huang, C.; Luo, Q.; Xiao, R.; Chen, Z.H. LncRNA PCAT19 induced by SP1 and acted as oncogene in gastric cancer competitively binding to miR429 and upregulating DHX9. J. Cancer 2022, 13, 102–111. [Google Scholar] [CrossRef]
  68. Hu, H.; Luo, H.; Deng, Z. PCAT19: The role in cancer pathogenesis and beyond. Front. Cell Dev. Biol. 2024, 12, 1435717. [Google Scholar] [CrossRef]
  69. Wang, H.S.; Zhang, W.; Zhu, H.-L.; Li, Q.-P.; Miao, L. Long noncoding RNA SNHG6 mainly functions as a competing endogenous RNA in human tumors. Cancer Cell Int. 2020, 20, 219. [Google Scholar] [CrossRef]
  70. Xu, C.; Liang, H.; Zhou, J.; Wang, Y.; Liu, S.; Wang, X.; Su, L.; Kang, X. lncRNA small nucleolar RNA host gene 12 promotes renal cell carcinoma progression by modulating the miR-200c-5p/collagen type XI alpha1 chain pathway. Mol. Med. Rep. 2020, 22, 3677–3686. [Google Scholar] [CrossRef]
  71. Huang, Y.; Xia, L.; Tan, X.; Zhang, J.; Zeng, W.; Tan, B.; Yu, X.; Fang, W.; Yang, Z. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis. Cell. Mol. Biol. Lett. 2022, 27, 43. [Google Scholar] [CrossRef]
  72. Liu, K.; Hou, Y.; Liu, Y.; Zheng, J. LncRNA SNHG15 contributes to proliferation, invasion and autophagy in osteosarcoma cells by sponging miR-141. J. Biomed. Sci. 2017, 24, 46. [Google Scholar] [CrossRef]
  73. Wu, D.M.; Wang, S.; Wen, X.; Han, X.R.; Wang, Y.J.; Shen, M.; Fan, S.H.; Zhang, Z.F.; Shan, Q.; Li, M.Q.; et al. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma. Cell Death Dis. 2018, 9, 947. [Google Scholar] [CrossRef]
  74. Ye, J.; Tan, L.; Fu, Y.; Xu, H.; Wen, L.; Deng, Y.; Liu, K. LncRNA SNHG15 promotes hepatocellular carcinoma progression by sponging miR-141-3p. J. Cell. Biochem. 2019, 120, 19775–19783. [Google Scholar] [CrossRef]
  75. Li, Y.; Lu, Y.; Chen, Y. Long non-coding RNA SNHG16 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer via sponging miR-200a-3p. Biosci. Rep. 2019, 39, BSR20182498. [Google Scholar] [CrossRef]
  76. Li, S.; Huang, Y.; Huang, Y.; Fu, Y.; Tang, D.; Kang, R.; Zhou, R.; Fan, X.G. The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation. J. Exp. Clin. Cancer Res. 2017, 36, 51. [Google Scholar] [CrossRef] [PubMed]
  77. Yao, J.; Xu, F.; Zhang, D.; Yi, W.; Chen, X.; Chen, G.; Zhou, E. TP73-AS1 promotes breast cancer cell proliferation through miR-200a-mediated TFAM inhibition. J. Cell. Biochem. 2018, 119, 680–690. [Google Scholar] [CrossRef] [PubMed]
  78. Miao, H.; Lu, J.; Guo, Y.; Qiu, H.; Zhang, Y.; Yao, X.; Li, X.; Lu, Y. LncRNA TP73-AS1 enhances the malignant properties of pancreatic ductal adenocarcinoma by increasing MMP14 expression through miRNA -200a sponging. J. Cell. Mol. Med. 2021, 25, 3654–3664. [Google Scholar] [CrossRef]
  79. Zhu, J.; Shi, H.; Liu, H.; Wang, X.; Li, F. Long non-coding RNA TUG1 promotes cervical cancer progression by regulating the miR-138-5p-SIRT1 axis. Oncotarget 2017, 8, 65264. [Google Scholar] [CrossRef]
  80. Zhang, B.; Zhao, C.; Hou, L.; Wu, Y. Silencing of the lncRNA TUG1 attenuates the epithelial-mesenchymal transition of renal tubular epithelial cells by sponging miR-141-3p via regulating beta-catenin. Am. J. Physiol. Renal Physiol. 2020, 319, F1125–F1134. [Google Scholar] [CrossRef] [PubMed]
  81. Liu, W.; Feng, Q.; Liao, W.; Li, E.; Wu, L. TUG1 promotes the expression of IFITM3 in hepatocellular carcinoma by competitively binding to miR-29a. J. Cancer 2021, 12, 6905–6920. [Google Scholar] [CrossRef]
  82. Yang, F.; Li, X.; Zhang, L.; Cheng, L.; Li, X. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. J. Pharmacol. Sci. 2018, 137, 116–121. [Google Scholar] [CrossRef]
  83. Wang, X.; Chen, X.; Han, W.; Ruan, A.; Chen, L.; Wang, R.; Xu, Z.; Xiao, P.; Lu, X.; Zhao, Y.; et al. miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma. Mol. Cancer Res. 2015, 13, 1567–1577. [Google Scholar] [CrossRef]
  84. Xu, R.; Zhu, X.; Chen, F.; Huang, C.; Ai, K.; Wu, H.; Zhang, L.; Zhao, X. LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells. Cancer Cell Int. 2018, 18, 41. [Google Scholar] [CrossRef]
  85. Zhu, H.; Zheng, T.; Yu, J.; Zhou, L.; Wang, L. LncRNA XIST accelerates cervical cancer progression via upregulating Fus through competitively binding with miR-200a. Biomed. Pharmacother. 2018, 105, 789–797. [Google Scholar] [CrossRef]
  86. Li, C.; Wan, L.; Liu, Z.; Xu, G.; Wang, S.; Su, Z.; Zhang, Y.; Zhang, C.; Liu, X.; Lei, Z.; et al. Long non-coding RNA XIST promotes TGF-beta-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. Cancer Lett. 2018, 418, 185–195. [Google Scholar] [CrossRef] [PubMed]
  87. Liu, W.-G.; Xu, Q. Long non-coding RNA XIST promotes hepatocellular carcinoma progression by sponging miR-200b-3p. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 9857–9862. [Google Scholar] [CrossRef]
  88. O’Brien, S.J.; Fiechter, C.; Burton, J.; Hallion, J.; Paas, M.; Patel, A.; Patel, A.; Rochet, A.; Scheurlen, K.; Gardner, S.; et al. Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell Death Discov. 2021, 7, 61. [Google Scholar] [CrossRef]
  89. Pillai, R.S. MicroRNA function: Multiple mechanisms for a tiny RNA? RNA 2005, 11, 1753–1761. [Google Scholar] [CrossRef]
  90. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [Google Scholar] [CrossRef]
  91. Zamore, P.D.; Haley, B. Ribo-gnome: The big world of small RNAs. Science 2005, 309, 1519–1524. [Google Scholar] [CrossRef]
  92. Wu, W.; Zhang, S.; He, J. The Mechanism of Long Non-coding RNA in Cancer Radioresistance/Radiosensitivity: A Systematic Review. Front. Pharmacol. 2022, 13, 879704. [Google Scholar] [CrossRef] [PubMed]
  93. Wooten, S.; Smith, K.N. Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes. Clin. Transl. Med. 2022, 12, e706. [Google Scholar] [CrossRef]
  94. Ghafouri-Fard, S.; Dashti, S.; Farsi, M.; Hussen, B.M.; Taheri, M. A review on the role of oncogenic lncRNA OIP5-AS1 in human malignancies. Biomed. Pharmacother. 2021, 137, 111366. [Google Scholar] [CrossRef]
  95. Liu, Y.; Cai, X.; Cai, Y.; Chang, Y. lncRNA OIP5-AS1 Suppresses Cell Proliferation and Invasion of Endometrial Cancer by Regulating PTEN/AKT via Sponging miR-200c-3p. J. Immunol. Res. 2021, 2021, 4861749. [Google Scholar] [CrossRef]
  96. Wang, Y.; Shi, F.; Xia, Y.; Zhao, H. LncRNA OIP5-AS1 predicts poor prognosis and regulates cell proliferation and apoptosis in bladder cancer. J. Cell. Biochem. 2019, 120, 7499–7505. [Google Scholar] [CrossRef]
  97. He, X.; Hou, J.; Ping, J.; Wen, D.; He, J. Opa interacting protein 5 acts as an oncogene in bladder cancer. J. Cancer Res. Clin. Oncol. 2017, 143, 2221–2233. [Google Scholar] [CrossRef]
  98. Zhang, S.F.; Pang, S.; Wang, F.P.; Li, X.Y.; Zou, Q. Long noncoding RNA OIP5-AS1 exhibits oncogenic activity in bladder cancer through miR-217 and MTDH. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 211–3220. [Google Scholar] [CrossRef]
  99. Esfandi, F.; Taheri, F.; Kiani, A.; Taheri, M.; Ghafouri-Fard, S. Expression analysis of OIP5-AS1 in bladder tissues. Genit. Mol. Res. 2018, 18, 260–263. [Google Scholar]
  100. Fu, J.X. LncRNA OIP5-AS1 induces epithelial-to-mesenchymal transition and renal fibrosis in diabetic nephropathy via binding to miR-30c-5p. J. Biol. Regul. Homeost. Agents 2020, 34, 961–968. [Google Scholar] [CrossRef]
  101. Hjazi, A.; Jasim, S.A.; Altalbawy, F.M.A.; Kaur, H.; Hamzah, H.F.; Kaur, I.; Deorari, M.; Kumar, A.; Elawady, A.; Fenjan, M.N. Relationship between lncRNA MALAT1 and Chemo-radiotherapy Resistance of Cancer Cells: Uncovered Truths. Cell Biochem. Biophys. 2024, 82, 1613–1627. [Google Scholar] [CrossRef]
  102. Fu, S.; Wang, Y.; Li, H.; Chen, L.; Liu, Q. Regulatory Networks of LncRNA MALAT-1 in Cancer. Cancer Manag. Res. 2020, 12, 10181–10198. [Google Scholar] [CrossRef]
  103. Wei, S.; Wang, K.; Huang, X.; Zhao, Z.; Zhao, Z. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int. J. Immunopathol. Pharmacol. 2019, 33, 2058738419859699. [Google Scholar] [CrossRef]
  104. Li, Q.; Zhang, C.; Chen, R.; Xiong, H.; Qiu, F.; Liu, S.; Zhang, M.; Wang, F.; Wang, Y.; Zhou, X.; et al. Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma. Cancer Lett. 2016, 383, 28–40. [Google Scholar] [CrossRef]
  105. Gou, L.; Zou, H.; Li, B. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1. Cancer Biol. Ther. 2019, 20, 1355–1365. [Google Scholar] [CrossRef] [PubMed]
  106. Zhao, Z.B.; Chen, F.; Bai, X.F. Long Noncoding RNA MALAT1 Regulates Hepatocellular Carcinoma Growth Under Hypoxia via Sponging MicroRNA-200a. Yonsei Med. J. 2019, 60, 727–734. [Google Scholar] [CrossRef]
  107. Huang, J.; Wang, X.; Wen, G.; Ren, Y. miRNA-205-5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells. Oncol. Rep. 2019, 42, 1677–1688. [Google Scholar] [CrossRef] [PubMed]
  108. Wapinski, O.; Chang, H.Y. Long noncoding RNAs and human disease. Trends Cell Biol. 2011, 21, 354–361. [Google Scholar] [CrossRef]
  109. Williams, A.E. Functional aspects of animal microRNAs. Cell. Mol. Life Sci. 2008, 65, 545–562. [Google Scholar] [CrossRef]
  110. Derrien, T.; Guigo, R.; Johnson, R. The Long Non-Coding RNAs: A New (P)layer in the “Dark Matter”. Front. Genet. 2011, 2, 107. [Google Scholar] [CrossRef]
  111. Shen, S.S.; Krishna, B.; Chirala, R.; Amato, R.J.; Truong, L.D. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod. Pathol. 2005, 18, 933–940. [Google Scholar] [CrossRef]
  112. Hay, E.D.; Zuk, A. Transformations between epithelium and mesenchyme: Normal, pathological, and experimentally induced. Am. J. Kidney Dis. 1995, 26, 678–690. [Google Scholar] [CrossRef]
  113. Abedi-Ardekani, B.; Nasrollahzadeh, D.; Egevad, L.; Banks, R.E.; Vasudev, N.; Holcatova, I.; Povysil, C.; Foretova, L.; Janout, V.; Mates, D.; et al. Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer. Virchows Arch. 2021, 478, 1099–1107. [Google Scholar] [CrossRef]
  114. Skinnider, B.F.; Folpe, A.L.; Hennigar, R.A.; Lim, S.D.; Cohen, C.; Tamboli, P.; Young, A.; de Peralta-Venturina, M.; Amin, M.B. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: Potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am. J. Surg. Pathol. 2005, 29, 747–754. [Google Scholar] [CrossRef]
  115. Coenye, T. Do results obtained with RNA-sequencing require independent verification? Biofilm 2021, 3, 100043. [Google Scholar] [CrossRef]
Cancers 17 03123 g001
Figure 1. Morphology of sarcomatoid renal cell carcinoma (sRCC). (A) Carcinomatous component of sRCC: nests of cells with abundant clear cytoplasm with small nuclei. A network of small vessels surrounds tumor nests, a characteristic feature of clear cell RCC (HE, orig. magnification 20×). (B) Sarcomatous component of sRCC: malignant spindle cells with pleomorphic nuclei growing in short irregular fascicles (HE, orig. magnification 20×).
Figure 1. Morphology of sarcomatoid renal cell carcinoma (sRCC). (A) Carcinomatous component of sRCC: nests of cells with abundant clear cytoplasm with small nuclei. A network of small vessels surrounds tumor nests, a characteristic feature of clear cell RCC (HE, orig. magnification 20×). (B) Sarcomatous component of sRCC: malignant spindle cells with pleomorphic nuclei growing in short irregular fascicles (HE, orig. magnification 20×).
Cancers 17 03123 g001
Cancers 17 03123 g002
Figure 2. Vascular invasion in clear cell renal cell carcinoma (ccRCC): a venous tumor thrombus filling and distending the lumen of a segmental renal vein in the renal hilum. The vessel wall is highlighted by asterisks (HE, orig. magnification 2×).
Figure 2. Vascular invasion in clear cell renal cell carcinoma (ccRCC): a venous tumor thrombus filling and distending the lumen of a segmental renal vein in the renal hilum. The vessel wall is highlighted by asterisks (HE, orig. magnification 2×).
Cancers 17 03123 g002
Cancers 17 03123 g003
Figure 3. Expression of miR-200 family in different entities of RCC and in different parts of RCC with renal vein invasion. Legend: ccRCC, clear cell renal cell carcinoma (n = 6); geomean, geometric mean; GOI, gene of interest; N, morphologically normal tissue adjunct to tumor (n = 6); n, number of biological replicates; RGs, reference genes; sRCC, sarcomatoid renal cell carcinoma; sRCC-Ca, carcinomatous component of sRCC (n = 6); sRCC-Sa, sarcomatoid component of sRCC (n = 6); TC, tumor center (n = 6); TP, tumor periphery (n = 6); VTT, venous tumor thrombus (n = 6); *, p < 0.05; **, p < 0.01. Each biological replicate was performed in two technical replicates, and, for ΔCq calculation, for each biological replicate, the average value of two technical replicates was used.
Figure 3. Expression of miR-200 family in different entities of RCC and in different parts of RCC with renal vein invasion. Legend: ccRCC, clear cell renal cell carcinoma (n = 6); geomean, geometric mean; GOI, gene of interest; N, morphologically normal tissue adjunct to tumor (n = 6); n, number of biological replicates; RGs, reference genes; sRCC, sarcomatoid renal cell carcinoma; sRCC-Ca, carcinomatous component of sRCC (n = 6); sRCC-Sa, sarcomatoid component of sRCC (n = 6); TC, tumor center (n = 6); TP, tumor periphery (n = 6); VTT, venous tumor thrombus (n = 6); *, p < 0.05; **, p < 0.01. Each biological replicate was performed in two technical replicates, and, for ΔCq calculation, for each biological replicate, the average value of two technical replicates was used.
Cancers 17 03123 g003
Cancers 17 03123 g004
Figure 4. Expression of analyzed lncRNAs as potential regulators of miR-200 family in early ccRCC, advanced ccRCC, and sRCC. Legend: ccRCC, clear cell renal cell carcinoma (n = 6); geomean, geometric mean; GOI, gene of interest; N, morphologically normal tissue adjunct to tumor (n = 6); n, number of biological replicates; RGs, reference genes; sRCC, sarcomatoid renal cell carcinoma; sRCC-Ca, carcinomatous component of sRCC (n = 6); sRCC-Sa, sarcomatoid component of sRCC (n = 6); TC, tumor center (n = 6); TP, tumor periphery (n = 6); VTT, venous tumor thrombus (n = 6); *, p < 0.05. Each biological replicate was performed in 2 technical replicates, and, for ΔCq calculation, for each biological replicate, the average value of two technical replicates was used.
Figure 4. Expression of analyzed lncRNAs as potential regulators of miR-200 family in early ccRCC, advanced ccRCC, and sRCC. Legend: ccRCC, clear cell renal cell carcinoma (n = 6); geomean, geometric mean; GOI, gene of interest; N, morphologically normal tissue adjunct to tumor (n = 6); n, number of biological replicates; RGs, reference genes; sRCC, sarcomatoid renal cell carcinoma; sRCC-Ca, carcinomatous component of sRCC (n = 6); sRCC-Sa, sarcomatoid component of sRCC (n = 6); TC, tumor center (n = 6); TP, tumor periphery (n = 6); VTT, venous tumor thrombus (n = 6); *, p < 0.05. Each biological replicate was performed in 2 technical replicates, and, for ΔCq calculation, for each biological replicate, the average value of two technical replicates was used.
Cancers 17 03123 g004
Cancers 17 03123 g005
Figure 5. Correlation between lncRNA (LINC00467, MALAT1, and OIP5-AS1) and miR-200 family expression in RCC (n = 42). Legend: ∆Cq, delta quantitation cycle (geometric mean of Cq of reference genes subtracted from Cq of gene of interest, e.g., lncRNA/miRNA); n, number of biological replicates. Each biological replicate was performed in 2 technical replicates, and, for ΔCq calculation, for each biological replicate, the average value of two technical replicates was used.
Figure 5. Correlation between lncRNA (LINC00467, MALAT1, and OIP5-AS1) and miR-200 family expression in RCC (n = 42). Legend: ∆Cq, delta quantitation cycle (geometric mean of Cq of reference genes subtracted from Cq of gene of interest, e.g., lncRNA/miRNA); n, number of biological replicates. Each biological replicate was performed in 2 technical replicates, and, for ΔCq calculation, for each biological replicate, the average value of two technical replicates was used.
Cancers 17 03123 g005
Cancers 17 03123 g006
Figure 6. Expression of miR-200 family in KIRC samples from TCGA. Legend: KIRC, kidney renal clear cell carcinoma (n = 511); N, morphologically normal tissue adjunct to tumor (n = 71); n, number of biological replicates; RPM, reads per million; TCGA, The Cancer Genome Atlas.
Figure 6. Expression of miR-200 family in KIRC samples from TCGA. Legend: KIRC, kidney renal clear cell carcinoma (n = 511); N, morphologically normal tissue adjunct to tumor (n = 71); n, number of biological replicates; RPM, reads per million; TCGA, The Cancer Genome Atlas.
Cancers 17 03123 g006
Cancers 17 03123 g007
Figure 7. Expression of LINC00467, MALAT1, and OIP5-AS1 in KIRC samples from TCGA. Legend: FPKM-UQ, fragments per kilobase of transcript per million mapped reads in the upper quartile; KIRC, kidney renal clear cell carcinoma (n = 511); N, morphologically normal tissue adjunct to tumor (n = 71); n, number of biological replicates; RPM, reads per million; TCGA, The Cancer Genome Atlas.
Figure 7. Expression of LINC00467, MALAT1, and OIP5-AS1 in KIRC samples from TCGA. Legend: FPKM-UQ, fragments per kilobase of transcript per million mapped reads in the upper quartile; KIRC, kidney renal clear cell carcinoma (n = 511); N, morphologically normal tissue adjunct to tumor (n = 71); n, number of biological replicates; RPM, reads per million; TCGA, The Cancer Genome Atlas.
Cancers 17 03123 g007
Table 1. Patient and tumor characteristics with tissue sample regions by group.
Table 1. Patient and tumor characteristics with tissue sample regions by group.
GroupAge
(Mean ± SD)		Male/FemaleTumor Size (Mean)Nuclear GradeTissue Samples
Early ccRCC62.7 ± 4.64:32.2 ± 0.72Non-Tumorous Kidney (n = 3)
Carcinoma (n = 6)
Advanced † ccRCC64.6 ± 8.910:06.3 ± 2.22 (n = 2)Non-Tumorous Kidney (n = 3)
Carcinoma–Central Part (n = 6)
3 (n = 7)Carcinoma–At Hilum (n = 6)
Venous Tumor Thrombus (n = 6)
sRCC §61.1 ± 13.46:28.9 ± 3.24Carcinomatous Component (n = 6)
Sarcomatous Component (n = 6)
Legend: ccRCC, clear cell renal cell carcinoma; early, pT1; † advanced ccRCC, pT3 ccRCC with venous invasion; § sRCC, sarcomatoid RCC. TNM staging was performed according to the latest TNM classification of renal tumors [26].
Table 2. Currently known interactions of 31 analyzed lncRNAs with miR-200 family members in various cancer types and disease states.
Table 2. Currently known interactions of 31 analyzed lncRNAs with miR-200 family members in various cancer types and disease states.
lncRNATarget miRNAAssociated DiseaseReferences
CCAT1miR-200bAnaplastic Thyroid
Carcinoma		[33]
CCAT2miR-200bEsophageal Squamous Cell Carcinoma[34]
GAS5miR-200 familyCOVID-19[35]
HOTAIRmiR-141, miR-200a, miR-200b, miR-200cRCC Cell Lines, Gastric
Carcinoma Cell Line,
Ovarian Carcinoma		[36,37,38]
LINC00341miR-141Osteoarthritis[39]
KCNQ1OT1miR-141/-200a/bOsteoporosis, Cerebral
Ischemic Stroke, Skin Wound Healing		[40,41,42]
LINC00467miR-200aGlioma Cell Line[43]
LINC00475miR-141Glioma[44]
LINC00641miR-429Gastric Cancer[45]
LINC00667miR-200b/c/429Wilms Tumor, Esophageal Carcinoma, Breast
Carcinoma,
Cholangiocarcinoma		[46,47,48,49]
LINC01234miR-429Breast Carcinoma[50]
LUCAT1miR-200cOsteosarcoma[51]
MAGI2-AS3miR-141/200aGastric Carcinoma[52]
MALAT1miR-200 familyRCC, Lung Carcinoma[53,54,55]
MEG3miR-141, miR-200a/cBreast Carcinoma, Lung
Carcinoma Cell Line		[56]
MIATmiR-141Gastric Carcinoma,
Osteosarcoma		[57,58]
MIR22HGmiR-141Endometrial Carcinoma,
Anaplastic Thyroid
Carcinoma		[59,60,61]
NEAT1miR-141, miR-200bEndometriosis, Breast
Carcinoma, Melanoma		[62,63,64]
OIP5-AS1miR-429, miR-200cLung Adenocarcinoma,
Pancreatic Adenocarcinoma, Endometrial Carcinoma		[65,66]
PCAT19miR-429Gastric Carcinoma, Lung
Adenocarcinoma		[67,68]
SNHG6miR-141, miR-429Osteosarcoma, Wilms Tumor[69]
SNHG12miR-200c, miR-429Renal Cell Carcinoma, Lung Adenocarcinoma[70,71]
SNHG15miR-141, miR-200aOsteosarcoma, Papillary Thyroid Carcinoma, Hepatocellular Carcinoma,
Nasopharyngeal Carcinoma		[72,73,74]
SNHG16miR-200aColorectal Carcinoma[75]
TP73-AS1miR-141, miR-200aHepatocellular Carcinoma, Pancreatic Ductal
Adenocarcinoma, Breast
Carcinoma		[76,77,78]
TUG1miR-138, miR-141Renal Interstitial Fibrosis
Cervical Carcinoma, Hepatocellular Carcinoma, Pancreatic Carcinoma		[79,80,81,82]
XISTmiR-141, miR-200a, miR-200b, miR-200c, miR-429Non-Small Cell Lung
Carcinoma, Hepatocellular Carcinoma, Bladder
Carcinoma, Hepatocellular Carcinoma, Cervical
Carcinoma		[83,84,85,86,87]
ZFAS1miR-200b, miR-200cColorectal Carcinoma[88]
Note: For MAGI1-IT1, TUNCAR, and UCA1, the suggested target miRNAs were miR-200a, miR-200a, and miR-200c in ovarian cancer, glioma, and hemangioma, respectively; however, all articles were retracted.
Table 3. Number of lncRNA targets per miR-200 family member in DIANA-LncBase v3, ENCORI, and RNA Interactome databases.
Table 3. Number of lncRNA targets per miR-200 family member in DIANA-LncBase v3, ENCORI, and RNA Interactome databases.
DatabasemiR-200amiR-200bmiR-200cmiR-141miR-429
DIANA-lncBase v3178140204229174
ENCORI2623242624
RNA Interactome116123118120131
Table 4. Common lncRNA targets across DIANA-lncBase v3, ENCORI, and RNA Interactome databases for each miR-200 family miRNA.
Table 4. Common lncRNA targets across DIANA-lncBase v3, ENCORI, and RNA Interactome databases for each miR-200 family miRNA.
miR-200amiR-200bmiR-200cmiR-141miR-429
MALAT1MALAT1MALAT1MALAT1MALAT1
SNHG16OIP5-AS1OIP5-AS1SNHG16OIP5-AS1
XISTXISTXISTXIST
Table 5. Common lncRNA targets across the miR-200 family identified within each database—DIANA-LncBase v3, ENCORI, and RNA Interactome.
Table 5. Common lncRNA targets across the miR-200 family identified within each database—DIANA-LncBase v3, ENCORI, and RNA Interactome.
DIANA-lncBase v3ENCORIRNA Interactome
AC010342.1AL049840.5AQP4-AS1
AL118506.1KCNQ1OT1ASTN2-AS1
AP000926.1MALAT1ATP2B1-AS1
GAS5NEAT1ATXN8OS
MALAT1OIP5-AS1C5orf56
NAP1L1P3XISTDRAIC
NEAT1 H19
OIP5-AS1 HAND2-AS1
PVT1 LINC00341
RPL23AP73 LINC00461
SNHG15 LINC00667
TDGP1 LINC01140
XIST LINC01312
XLOC_006069 LINC02120
XLOC_008185 LOC256880
LOC285074
LOC401021
MALAT1
MSC-AS1
PART1
TTTY4B
ZEB1-AS1
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Čugura, T.; Hauptman, N.; Jeruc, J.; Boštjančič, E. Investigating the Relationship Between Long Non-Coding RNAs and miR-200 Family Expression in Clear Cell Renal Cell Carcinoma. Cancers 2025, 17, 3123. https://doi.org/10.3390/cancers17193123

AMA Style

Čugura T, Hauptman N, Jeruc J, Boštjančič E. Investigating the Relationship Between Long Non-Coding RNAs and miR-200 Family Expression in Clear Cell Renal Cell Carcinoma. Cancers. 2025; 17(19):3123. https://doi.org/10.3390/cancers17193123

Chicago/Turabian Style

Čugura, Tanja, Nina Hauptman, Jera Jeruc, and Emanuela Boštjančič. 2025. "Investigating the Relationship Between Long Non-Coding RNAs and miR-200 Family Expression in Clear Cell Renal Cell Carcinoma" Cancers 17, no. 19: 3123. https://doi.org/10.3390/cancers17193123

APA Style

Čugura, T., Hauptman, N., Jeruc, J., & Boštjančič, E. (2025). Investigating the Relationship Between Long Non-Coding RNAs and miR-200 Family Expression in Clear Cell Renal Cell Carcinoma. Cancers, 17(19), 3123. https://doi.org/10.3390/cancers17193123

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop